1 / 3

HITPC - Information Exchange Work Group Meaningful Use Stage 3 Subgroup 1 Quality and Efficiency

HITPC - Information Exchange Work Group Meaningful Use Stage 3 Subgroup 1 Quality and Efficiency. Chair: Dave Goetz Members: Cris Ross, Chris Tashjian , Steve Stack. How can these areas be addressed in the context of MU Stage 3?. Administrative simplification Clinical Decision Support

wells
Télécharger la présentation

HITPC - Information Exchange Work Group Meaningful Use Stage 3 Subgroup 1 Quality and Efficiency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HITPC - Information Exchange Work GroupMeaningful Use Stage 3 Subgroup 1Quality and Efficiency Chair: Dave Goetz Members: Cris Ross, Chris Tashjian, Steve Stack

  2. How can these areas be addressed in the context of MU Stage 3? • Administrative simplification • Clinical Decision Support • E-prescribing • Questions: • Can the MU framework effectively be used to address those electronic transactions not currently in Stage 1 or Stage 2 as proposed (admin)? • Which Stage 1 or Stage 2 (proposed) objectives should be expanded? • Are there new objectives that need to be created? • Are there Stage 1 or Stage 2 objectives to be deleted or consolidated?

  3. Proposed short term thoughts • Administrative simplification • Which transaction areas could be considered? • Prior authorizations, eligibility checks, claims processing/editing • Which are already addressed in the market? • How would the MU framework address this area? • What would be effective for EHR vendors and providers? • Clinical Decision Support • Await final MU 2 regulations, recommendations from MU WG • E-prescribing • What areas of eRx remain unaddressed? (controlled substances, mail order pharmacies)

More Related